Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Repligen Corporation Shares Were Slammed

By Sean Williams - Mar 6, 2014 at 1:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Repligen shares sink after the company reports its fourth-quarter earnings results. Is this dip a buying opportunity or a reason to keep your distance.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Repligen ( RGEN -1.61% ), a life-sciences company that develops consumable products used in the process of manufacturing biological drugs, fell as much as 16% after reporting its fourth-quarter earnings results before the opening bell.

So what: According to its report, Repligen delivered total quarterly revenue of $15.4 million, an 18.2% decrease from the year-ago quarter, as adjusted EPS fell by two-thirds to just $0.10 from $0.30. Repligen blamed its reduced revenue on a one-time out-licensing agreement with Pfizer that resulted in a $5 million upfront payment last year, but no payment this year. By comparison, Wall Street estimates had pegged Repligen for $15.9 million in revenue and $0.14 in EPS, meaning it missed on both accounts. If there was a bright spot, it was that Repligen's bioprocessing revenue jumped nearly 7% to $10.4 million.

Looking ahead to fiscal 2014, Repligen issued guidance calling for revenue in the $54 million-$57 million range, including product-revenue growth of 10%-15%. Net income for the year is expected to total $7 million-$9 million, or $0.21-$0.28 in EPS. This estimate, however, bracketed a bit higher than the Street's consensus of $53.1 million and $0.22 in EPS for the full year.

Now what: I wouldn't be too surprised by today's move lower because Repligen doesn't have a lot of Wall Street coverage and is liable to be whipsawed for beating or missing the one or two estimates available. The key takeaway here is that Repligen's bioprocessing business, which is its bread and butter, has the potential to grow organically by low double digits. This seems like a pretty fair growth target for the remainder of the decade, yet I'm still a bit taken back by its projected P/E for 2014, which is close to 60 at the moment. While I appreciate Repligen's organic growth, I'd rather watch it from the sidelines until its bottom-line profit catches up with its current valuation.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Repligen Corporation Stock Quote
Repligen Corporation
RGEN
$286.50 (-1.61%) $-4.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.